Galecto shares are trading lower after the company announced topline results from its Phase 2b GALACTIC-1 trial of GB0139 for idiopathic pulmonary fibrosis, which showed the trial did not meet its primary endpoint. The company plans to discontinue development of GB0139.
Benzinga Newsdesk - Aug 15, 2023, 9:02AM